These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

568 related articles for article (PubMed ID: 20925074)

  • 1. Comparison of orally dissolving carbidopa/levodopa (Parcopa) to conventional oral carbidopa/levodopa: A single-dose, double-blind, double-dummy, placebo-controlled, crossover trial.
    Ondo WG; Shinawi L; Moore S
    Mov Disord; 2010 Dec; 25(16):2724-7. PubMed ID: 20925074
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses.
    Okereke CS; Kirby L; Kumar D; Cullen EI; Pratt RD; Hahne WA
    Br J Clin Pharmacol; 2004 Nov; 58 Suppl 1(Suppl 1):41-9. PubMed ID: 15496222
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A multicenter, open-label, sequential study comparing preferences for carbidopa-levodopa orally disintegrating tablets and conventional tablets in subjects with Parkinson's disease.
    Nausieda PA; Pfeiffer RF; Tagliati M; Kastenholz KV; DeRoche C; Slevin JT
    Clin Ther; 2005 Jan; 27(1):58-63. PubMed ID: 15763606
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease.
    Nyholm D; Nilsson Remahl AI; Dizdar N; Constantinescu R; Holmberg B; Jansson R; Aquilonius SM; Askmark H
    Neurology; 2005 Jan; 64(2):216-23. PubMed ID: 15668416
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reducing dosing frequency of carbidopa/levodopa: double-blind crossover study comparing twice-daily bilayer formulation of carbidopa/levodopa (IPX054) versus 4 daily doses of standard carbidopa/levodopa in stable Parkinson disease patients.
    Hinson VK; Goetz CG; Leurgans S; Fan W; Nguyen T; Hsu A
    Clin Neuropharmacol; 2009; 32(4):189-92. PubMed ID: 19620848
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Melevodopa/carbidopa effervescent formulation in the treatment of motor fluctuations in advanced Parkinson's disease.
    Stocchi F; Zappia M; Dall'Armi V; Kulisevsky J; Lamberti P; Obeso JA;
    Mov Disord; 2010 Sep; 25(12):1881-7. PubMed ID: 20669296
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fluctuations in plasma levodopa and motor responses with liquid and tablet levodopa/carbidopa.
    Metman LV; Hoff J; Mouradian MM; Chase TN
    Mov Disord; 1994 Jul; 9(4):463-5. PubMed ID: 7969216
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sinemet CR in Parkinson's disease.
    Pfeiffer RF; Wilken KE; Glaeske CS; Hofman R
    Nebr Med J; 1991 Jan; 76(1):8-10. PubMed ID: 1997878
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of methylphenidate on response to oral levodopa: a double-blind clinical trial.
    Nutt JG; Carter JH; Carlson NE
    Arch Neurol; 2007 Mar; 64(3):319-23. PubMed ID: 17353373
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical experience in switching patients from standard levodopa to a controlled-release levodopa].
    Leiva Santana C; Galvañ Berenguer B; Gómez García J; Cabello López J
    Neurologia; 1996 Jan; 11(1):1-9. PubMed ID: 8714169
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Pharmacokinetic comparison of Sinemet and Grifoparkin (levodopa/carbidopa 250/25 mg) in Parkinson s disease: a single dose study].
    Chaná P; Fierro A; Reyes-Parada M; Sáez-Briones P
    Rev Med Chil; 2003 Jun; 131(6):623-31. PubMed ID: 12942590
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Parcopa: a rapidly dissolving formulation of carbidopa/levodopa.
    Med Lett Drugs Ther; 2005 Jan; 47(1201):12. PubMed ID: 15706700
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized trial of IPX066, carbidopa/levodopa extended release, in early Parkinson's disease.
    Pahwa R; Lyons KE; Hauser RA; Fahn S; Jankovic J; Pourcher E; Hsu A; O'Connell M; Kell S; Gupta S;
    Parkinsonism Relat Disord; 2014 Feb; 20(2):142-8. PubMed ID: 24055014
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of standard carbidopa-levodopa and sustained-release carbidopa-levodopa in Parkinson's disease: pharmacokinetic and quality-of-life measures.
    Pahwa R; Lyons K; McGuire D; Silverstein P; Zwiebel F; Robischon M; Koller WC
    Mov Disord; 1997 Sep; 12(5):677-81. PubMed ID: 9380047
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A multicenter double-blind placebo-controlled trial of pergolide as an adjunct to Sinemet in Parkinson's disease.
    Olanow CW; Fahn S; Muenter M; Klawans H; Hurtig H; Stern M; Shoulson I; Kurlan R; Grimes JD; Jankovic J
    Mov Disord; 1994 Jan; 9(1):40-7. PubMed ID: 8139604
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The effect of controlled release of DOPA and carbidopa on clinical response and plasma pharmacokinetics of DOPA in parkinsonian patients].
    García de Yébenes J; Mateo D; Pino MA; Cordero M; Pastor M; Chacón J; Morales B; Sánchez V; Mena MA; Giménez Roldán S
    Neurologia; 1997 Apr; 12(4):145-56. PubMed ID: 9235023
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of piribedil as early combination to levodopa in patients with stable Parkinson's disease: a 6-month, randomized, placebo-controlled study.
    Ziegler M; Castro-Caldas A; Del Signore S; Rascol O
    Mov Disord; 2003 Apr; 18(4):418-25. PubMed ID: 12671949
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Continuous dopaminergic stimulation by Duodopa in advanced Parkinson's disease: Efficacy and safety].
    Annic A; Devos D; Seguy D; Dujardin K; Destée A; Defebvre L
    Rev Neurol (Paris); 2009; 165(8-9):718-27. PubMed ID: 19150100
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Levodopa + carbidopa + entacapone. Entacapone: a second look: new preparations. Parkinson's disease: a modest effect.
    Prescrire Int; 2005 Apr; 14(76):51-4. PubMed ID: 15875340
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of deprenyl and levodopa on the progression of Parkinson's disease.
    Olanow CW; Hauser RA; Gauger L; Malapira T; Koller W; Hubble J; Bushenbark K; Lilienfeld D; Esterlitz J
    Ann Neurol; 1995 Nov; 38(5):771-7. PubMed ID: 7486869
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.